Publishing research using ab32578? Please let us know so that we can cite the reference in this datasheet.

ab32578 has been referenced in 19 publications.

  • Milewska M  et al. Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers. Ther Adv Med Oncol 10:1758834017746040 (2018). PubMed: 29383036
  • Elster N  et al. Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer. Ther Adv Med Oncol 10:1758835918778297 (2018). PubMed: 30023006
  • Randall EC  et al. Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma. Nat Commun 9:4904 (2018). PubMed: 30464169
  • Andrejeva D  et al. Metabolic control of PPAR activity by aldehyde dehydrogenase regulates invasive cell behavior and predicts survival in hepatocellular and renal clear cell carcinoma. BMC Cancer 18:1180 (2018). PubMed: 30486822
  • Bönisch M  et al. Novel CH1:CL interfaces that enhance correct light chain pairing in heterodimeric bispecific antibodies. Protein Eng Des Sel 30:685-696 (2017). PubMed: 28981885
  • Gustafsson H  et al. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model. Cell Biochem Biophys 75:299-309 (2017). IHC . PubMed: 28756482
  • Thomas R  et al. Epidermal growth factor prevents APOE4-induced cognitive and cerebrovascular deficits in female mice. Heliyon 3:e00319 (2017). IHC-P ; Mouse . PubMed: 28626809
  • Lisse TS & Rieger S IKKa regulates human keratinocyte migration through surveillance of the redox environment. J Cell Sci 130:975-988 (2017). PubMed: 28122935
  • Zhou J  et al. Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling. Oncotarget 8:103167-103181 (2017). WB . PubMed: 29262554
  • Kelsey JS  et al. The C1 domain of Vav3, a novel potential therapeutic target. Cell Signal 40:133-142 (2017). PubMed: 28927664
  • Chang YL  et al. Regulation of estrogen receptor a function in oral squamous cell carcinoma cells by FAK signaling. Endocr Relat Cancer 21:555-65 (2014). Human . PubMed: 24825747
  • Gerdes CA  et al. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res 19:1126-38 (2013). PubMed: 23209031
  • Hsieh TH  et al. Phthalates stimulate the epithelial to mesenchymal transitionthrough an HDAC6-dependent mechanism in human breast epithelial stem cells. Toxicol Sci 128:365-76 (2012). Human . PubMed: 22552774
  • Katayama R  et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 4:120ra17 (2012). WB ; Human . PubMed: 22277784
  • Wang YC  et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation. Breast Cancer Res 13:R121 (2011). WB . PubMed: 22123186
  • Balla P  et al. Epidermal growth factor receptor signalling contributes to osteoblastic stromal cell proliferation, osteoclastogenesis and disease progression in giant cell tumour of bone. Histopathology 59:376-89 (2011). IHC ; Human . PubMed: 22034878
  • Pickl M & Ries CH Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 28:461-8 (2009). PubMed: 18978815
  • Kumar N  et al. Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells. Mol Pharmacol 73:1668-78 (2008). PubMed: 18349105
  • Mahller YY  et al. Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther 15:279-86 (2007). WB . PubMed: 17235305

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up